Journal of Vascular and Interventional Radiology
Volume 19, Issue 3 , Pages 309-318 , March 2008

N-Acetylcysteine Use to Prevent Contrast Medium–induced Nephropathy: Premature Phase III Trials

  • David A. Stenstrom

      Affiliations

    • Department of Neurology, Oregon Health & Science University, Portland, Oregon
    • ,
  • Leslie L. Muldoon, PhD

      Affiliations

    • Department of Neurology, Oregon Health & Science University, Portland, Oregon
    • Department of Cell and Developmental Biology, Oregon Health & Science University, Portland, Oregon
    • ,
  • Hector Armijo-Medina, MD

      Affiliations

    • Department of Neurology, Oregon Health & Science University, Portland, Oregon
    • ,
  • Suzanne Watnick

      Affiliations

    • Division of Hospital and Specialty Medicine, Nephrology Section, Portland, Oregon
    • ,
  • Nancy D. Doolittle, PhD

      Affiliations

    • Department of Neurology, Oregon Health & Science University, Portland, Oregon
    • ,
  • John A. Kaufman, MD

      Affiliations

    • Department of Angiography, Oregon Health & Science University, Portland, Oregon
    • ,
  • Darryl R. Peterson, PhD

      Affiliations

    • Department of Physiology and Biophysics, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, North Chicago, Illinois.
    • ,
  • Joseph Bubalo, PharmD

      Affiliations

    • Pharmacy Department, Oregon Health & Science University, Portland, Oregon
    • ,
  • Edward A. Neuwelt, MD

      Affiliations

    • Department of Neurology, Oregon Health & Science University, Portland, Oregon
    • Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon
    • Portland Veterans Administration Medical Center, Portland, Oregon
    • Corresponding Author InformationAddress correspondence to E.A.N., Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Parkway, L603, Portland, OR 97239

Received 16 August 2007 ,Revised 31 October 2007 ,Accepted 1 November 2007.

References 

  1. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184
  2. Schultz MJ, Baas MC, van der Sluijs HP, Stamkot GA, Smit W. N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit. Curr Med Chem. 2006;13:2565–2570
  3. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K–13K
  4. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
  5. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114–2118
  6. Solomon R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int. 2006;69(suppl S100):S46–S50
  7. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298–303
  8. Weisbord SD, Palevsky PM. Radiocontrast-induced acute renal failure. J Intens Care Med. 2005;20:63–75
  9. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356–358
  10. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K–20K
  11. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499
  12. Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int. 2005;68:2250–2255
  13. Gulel O, Keles T, Eraslan H, Aydogdu S, Diker E, Ulusoy V. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. J Cardiovasc Pharmacol. 2005;46:464–467
  14. Solomon R, Biguori C, Bettmann M. Selection of contrast media. Kidney Int. 2006;69(suppl):S39–S45
  15. Vlietstra RE, Nunn CM, Narvarte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J. 1996;132:1049–1050
  16. Sandhu C, Newman DJ, Morgan R, Belli AM, Oliveira D. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol. 2002;9(suppl 2):S436–S437
  17. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int. 2006;(suppl):S16–S19
  18. Molnar Z, MacKinnon KL, Shearer E, Lowe D, Watson ID. The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients. Intens Care Med. 1998;24:230–235
  19. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31:217–222
  20. Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl. 1980;111:45–51
  21. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?. Pharmacotherapy. 2005;25:1095–1103
  22. Skrzydlewska E, Farbiszewski R. Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol Depend. 1999;57:61–67
  23. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60:6–20
  24. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hearing Res. 2004;193:25–30
  25. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34:77–82
  26. Tsikas D, Sandmann J, Ikic M, Fauler J, Stichtenoth DO, Frolich JC. Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. J Chromatogr B Biomed Sci Appl. 1998;708:55–60
  27. Lewis PA, Woodward AJ, Maddock J. Improved method for the determination of N-acetylcysteine in human plasma by high-performance liquid chromatography. J Chromatogr. 1985;327:261–267
  28. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36:127–131
  29. Brown M, Bjorksten A, Medved I, McKenna M. Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol. 2004;60:717–723
  30. Doolittle N, Lacy C, Tyson R, Haluska M, et al. Phase I study of N-acetylcysteine administered in the descending aorta in conjunction with carboplatin-based blood-brain barrier disruption (BBBD) in subjects with malignant brain tumors. Neuro-Oncology. 2003;5:350
  31. Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res. 2001;61:7868–7874
  32. Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Neuwelt EA. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother Pharmacol. 2007;[Epub ahead of print, Oct]
  33. ACETADOTE (acetylcysteine) injection [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals; 2004;
  34. Kao LW, Kirk MA, Furbee RB, Mehta NH, Skinner JR, Brizendine EJ. What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?. Ann Emerg Med. 2003;42:741–750
  35. Marzullo L. An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr. 2005;17:239–245
  36. Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J. 2002;19:594–595
  37. Vale JA, Wheeler DC. Anaphylactoid reaction to acetylcysteine. Lancet. 1982;2:988
  38. Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed). 1984;289:217–219
  39. Dawson AH, Henry DA, McEwen J. Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust. 1989;150:329–331
  40. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553–558
  41. Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart. 2005;91:774–778
  42. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006;151:1032;e1039–e1012
  43. Carbonell N, Blasco M, Sanjuan R, et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol. 2007;115:57–62
  44. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206–211
  45. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Cathet Cardiovasc Intervent. 2003;58:336–341
  46. Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invas Cardiol. 2005;17:80–84
  47. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383–1388
  48. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422–429
  49. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40:1136–1141
  50. Kotlyar E, Keogh AM, Thavapalachandran S, et al. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures–a randomised controlled trial. Heart Lung Circ. 2005;14:245–251
  51. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:E23
  52. Tadros GM, Mouhayar EN, Akinwande AO, Campbell B, Wood C, Blankenship JA. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invas Cardiol. 2003;15:311–314
  53. MacNeill BD, Harding SA, Bazari H, et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Cathet Cardiovasc Intervent. 2003;60:458–461
  54. Efrati S, Dishy V, Averbukh M, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003;64:2182–2187
  55. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17:159–165
  56. Miner SE, Dzavik V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690–695
  57. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004;19:1803–1807
  58. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc Intervent. 2002;57:279–283
  59. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207
  60. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography (A randomized controlled trial and review of the current literature). Eur Heart J. 2004;25:212–218
  61. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?. Acta Cardiol. 2003;58:555–560
  62. Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004;43:801–808
  63. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43:1–9
  64. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598–603
  65. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Cathet Cardiovasc Intervent. 2005;64:471–479
  66. Guru V, Fremes SE. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol. 2004;62:77–83
  67. Isenbarger DW, Kent SM, O’Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454–1458
  68. Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy (A systematic review and meta-analysis). J Gen Intern Med. 2005;20:193–200
  69. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. 2004;27:607–610
  70. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? (A meta-analysis). Am J Med. 2004;117:938–947
  71. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366–1374
  72. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2:38
  73. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761–769
  74. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140–145

 E.A.N., L.L.M., Oregon Health & Science University, Portland Veterans Affairs Medical Center, and the Department of Veterans Affairs have significant financial interest in Adherex (Durham, NC), a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest was reviewed and managed by the Oregon Health & Science University Integrity Program Oversight Council and the Portland Veterans Affairs Medical Center Conflict of Interest in Research Committee. E.A.N. has divested his financial interests in Adherex. This work was supported by a Veterans Administration Merit Review Grant and by National Institutes of Health grants NS33618 and NS44687 from the National Institute of Neurological Disorders and Stroke to E.A.N.

PII: S1051-0443(07)01434-0

doi: 10.1016/j.jvir.2007.11.003

Journal of Vascular and Interventional Radiology
Volume 19, Issue 3 , Pages 309-318 , March 2008

Article Tools

* Image Usage & Resolution